When was Desentum founded?

Desentum was founded in 2011 and raised its 1st funding round 5 years after it was founded.

Where is Desentum located?

Desentum is headquartered in Espoo, Finland.

Who is the current CEO of Desentum?

Pekka Mattila of Desentum. They have also founded 1 company.

How many employees does Desentum have?

As of Aug 31, 2026, the latest employee count at Desentum is 14.

Is Desentum a funded company?

Desentum is a funded company, having raised a total of $26.7M across 8 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on 2016.

When was the latest funding round of Desentum?

Desentum's latest funding was a $***** Series C round on Feb 20, 2024, with participation from 1 investor. Its primary sector is Immunology. Globally, the Immunology sector has seen $4.88B in funding in 2026 to date.

Where does Desentum rank among its competitors?

Desentum ranks 9th amongst 153 active competitors, of which 46 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Mabylon, which secured $37M in Aug, 2025.

Who are the top competitors of Desentum?

Desentum's top competitors include HOOKIPA Pharma, Bharat Biotech and Valneva. Among them, Mabylon secured the most recent funding round in August, 2025.

Desentum - 2026 Company Profile, Team, Funding & Competitors

Desentum is a series C company based in Espoo (Finland), founded in 2011 by Janne Janis, Pekka Mattila, Juha Rouvinen and Kristiina Takkinen. It operates as a Developing novel types of allergen immunotherapy products (allergy vaccines). Desentum has raised $26.7M in funding from investors like Springvest, Cascara Ventures and Voima Ventures. The company has 153 active competitors, including 46 funded and 32 that have exited. Its top competitors include companies like HOOKIPA Pharma, Bharat Biotech and Valneva.

Company Details

Desentum is a research-oriented biopharmaceutical company specialized in developing novel types of allergen immunotherapy products that are based on switching the immune system's response to allergens from hypersensitivity to tolerance. By studying the molecular mechanism of the hypersensitivity reaction, the company has made discoveries that allow for improved design of immunotherapeutic products against common types of allergies. The company will be starting clinical trials for the first hypoallergens in 2017.

Key Metrics

Founded Year

2011

Location

Espoo, Finland

Stage

Series C

Total Funding

$26.7M in 8 rounds

Latest Funding Round

Series C, Feb 20, 2024, $*****

Investors

Springvest & 5 more

Ranked

9^th among 153 active competitors

Employee Count

14 as on Aug 31, 2026

Similar Companies

HOOKIPA Pharma & 188 more

View Desentum's full profile

Desentum has raised a total funding of $26.7M over 8 rounds. Its first funding round was on 2016. Its latest funding round was a Series C round on Feb 20, 2024 for $*****. 1 investor participated in its latest round. Desentum has 6 institutional investors.

Here is the list of recent funding rounds of Desentum:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 20, 2024	1431418	Series C	7093311	3106961	1868127	8034152
Jan 21, 2022	7573167	Series B	8651527	8343558	5744616	2534154
Jul 31, 2021	4088157	Grant (prize money)	2642605	9974449	5922805	EIC Fund

Access funding benchmarks and valuations. Sign up today!

View details of Desentum's funding rounds and investors

The founders of Desentum are Janne Janis, Pekka Mattila, Juha Rouvinen and Kristiina Takkinen. Pekka Mattila is the CEO of Desentum.

Here are the details of Desentum's key team members:

Janne Janis: Co-Founder of Desentum.
Pekka Mattila: Co-Founder & CEO of Desentum.
Contact Info: 1 email address
Juha Rouvinen: Co-Founder of Desentum.
Kristiina Takkinen: Co-Founder of Desentum.

View details of Desentum's Founder profiles and Board Members

Desentum's employee count trend

Desentum has 14 employees as of Aug 26. Here is Desentum's employee count trend over the years:

Uncover Desentum's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Desentum include HOOKIPA Pharma, Bharat Biotech and Valneva. Here is the list of Top 10 competitors of Desentum, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	HOOKIPA Pharma 2011, Vienna (Austria), Public	Developer of immunotherapies for the treatment of infectious diseases and cancer	$134M	Sofinnova Partners, Forbion & 12 others	69/100
2nd	Bharat Biotech 1996, Hyderabad (India), Early Stage	Manufacturer of vaccines and bio-therapeutic products	$13.7M	ICICI Venture, IFC & 25 others	68/100
3rd	Valneva 1999, Lyon (France), Public	Developer of prophylactic vaccines for infectious diseases	$114M	Phase4 Partners, Eiffel Investment Group ... & 13 others	67/100
4th	Stallergenes Greer 2013, London (United Kingdom), Acquired	Developing allergen immunotherapy (vaccine) for respiratory allergies	-	Waypoint Capital, B-FLEXION	62/100
5th	Immunomic Therapeutics 2005, Rockville (United States), Series B	Vaccines for allergy, cancer and infectious disease.	$104M	HLB, Defense.gov & 7 others	62/100
6th	Mabylon 2015, Schlieren (Switzerland), Series B	Developer of therapeutics for allergies and neurodegenerative diseases	$37M	Admin, EIC Fund & 3 others	60/100
7th	RAPT 2015, San Francisco (United States), Acquired	Provider of immunology-based drug for oncology and inflammatory diseases	$199M	The Column Group, Celgene & 19 others	59/100
8th	Curevo 2017, Seattle (United States), Series B	Developer of non-mRNA adjuvanted subunit vaccines for infectious disease prevention	$196M	RA Capital Management, Janus Henderson Investors ... & 9 others	56/100
9th	Desentum 2011, Espoo (Finland), Series C	Developing novel types of allergen immunotherapy products (allergy vaccines)	$26.7M	EIC Fund, European Innovation Council & 4 others	55/100
10th	Biofarma 1890, Bandung (Indonesia), Funding Raised	Manufacturer of vaccines for multiple therapeutic areas	-	HSBC, Bill & Melinda Gates Foundation & 2 others	55/100